文献速递皮肤肿瘤

维布妥昔单抗治疗CD30+皮肤淋巴瘤:治疗现状与优化方向综述

Brentuximab vedotin in CD30+ cutaneous lymphoma: How do we treat, how shall we treat? A review of the literature.
PubMed 文献 · Br J Dermatol · 2017-11-22

本文系统综述PubMed与Cochrane对照试验中心注册库截至2016年4月的文献,评估CD30+皮肤淋巴瘤中维布妥昔单抗的用药方案。维布妥昔单抗对难治性CD30+CTCL有效,减量或延长间隔可能维持疗效并减少不良反应。

要点

  • 减量或延长间隔可能不损失疗效且不良反应更少。

核心结论

  • 维布妥昔单抗是难治性CD30+CTCL的有力治疗选择。
  • 减量或延长治疗间隔可能维持疗效并减少不良反应,但证据有限。

研究设计与样本

  • 系统综述,检索PubMed与Cochrane对照试验中心注册库截至2016年4月的文献,遵循PRISMA标准。

主要发现

  • 未检索到CD30+CTCL的剂量探索研究。
  • 存在减量及延长间隔不损失疗效且不良反应更少的趋势。

临床怎么用

  • 减量或延长间隔需个体化评估,缺乏剂量探索证据支持。

局限性

  • 检索截止2016年4月,未纳入后续研究。
  • 无CD30+CTCL剂量探索研究,减量证据仅来自2例个案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Brentuximab vedotin is an antibody-drug conjugate that brings the antimicrotubule agent monomethyl auristatin E into CD30-expressing cells. Some prior studies demonstrated good efficacy in cutaneous lymphomas. The standard therapeutic scheme is 1·8 mg kg-1 every 3 weeks. The background of this work is the fact that cutaneous lymphoma has a different pathophysiology and a dynamic other than systemic lymphomas. The objectives of this review were to get an overview of the currently used therapeutic regimen, and to check whether dose reduction or modified time intervals could be of benefit in a similar way with less toxicity. Therefore, we conducted a systematic review of the literature indexed in PubMed and the Cochrane Central Register of Controlled Trials up to April 2016. The procedure was based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria. The review showed that the currently used therapeutic regimen is 1·8 mg kg-1 every 3 weeks. No publications of dose-finding studies in CD30+ cutaneous T-cell lymphoma (CTCL) were found. Two cases of patients, treated with a dose < 1·8 mg kg-1 , have been published. Brentuximab vedotin seems to be a powerful treatment option in refractory CD30+ CTCL, and there is a trend that dose reductions, as well as prolonged treatment intervals, work without any loss of response and with fewer side-effects.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Stranzenbach R, Dippel E, Schlaak M, et al. Brentuximab vedotin in CD30+ cutaneous lymphoma: How do we treat, how shall we treat? A review of the literature. Br J Dermatol. 2017. PMID: 28703284. doi:10.1111/bjd.15801

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。